Quantum Biopharma Ltd. annual report, Q4 FY2021

Abrir documento

FSD Pharma Inc. — Form 20-F Summary

Business context and reporting period

The filing is FSD Pharma Inc.’s annual report for the fiscal year ended December 31, 2021, filed March 30, 2022. The source filing identifies FSD Pharma Inc., not Quantum Biopharma Ltd.; the requested company metadata therefore does not match the filing. Financial statements are audited and prepared under IFRS in U.S. dollars.

FSD is an early-stage biotechnology company with no commercialized products or pharmaceutical sales. Its principal candidates are FSD-PEA, an anti-inflammatory compound, and Lucid-MS and Lucid-PSYCH, acquired through the September 2021 Lucid transaction. The Company exited cannabis operations, surrendered its cannabis licenses in July 2020, and classified the former FV Pharma facility and property as held for sale.

Financial performance and position

  • Revenue: No revenue from continuing operations or product sales. Discontinued cannabis operations generated no revenue in 2021, compared with $14,514 in 2020.
  • Net loss: $35.285 million, compared with $31.800 million in 2020. Continuing-operations loss was $33.938 million versus $28.452 million.
  • Operating expenses: $33.744 million, up from $30.691 million. General and administrative expense increased to $15.926 million from $10.058 million; external research and development fees declined to $6.328 million from $7.833 million.
  • Share-based compensation: $7.444 million, compared with $8.052 million in 2020.
  • Loss per share: Basic and diluted loss per share was $0.97 from continuing operations and $0.04 from discontinued operations, compared with $2.36 and $0.28, respectively, in 2020. The lower per-share loss reflects a substantially larger share base.
  • Cash flow: Cash used in operating activities was $20.746 million, including $19.364 million from continuing operations and $1.382 million from discontinued operations, compared with $19.130 million in 2020. Financing provided $38.212 million, principally from share issuances.
  • Liquidity: Cash was $35.260 million at year-end, compared with $17.525 million. Current assets were $45.933 million and current liabilities were $8.701 million, implying reported current assets of approximately 5.3 times current liabilities.
  • Debt: The Company reported no long-term debt. Notes payable totaled $0.301 million, were assumed with the Prismic acquisition, had matured, and were due on demand. Lease obligations totaled $0.255 million.
  • Equity: Shareholders’ equity was $54.131 million, compared with $36.309 million. Accumulated deficit increased to $126.154 million from $90.869 million.
  • Assets held for sale: The former facility and property were carried at $8.648 million. A subsequent agreement provides for a sale price of C$16.5 million, including a C$0.660 million deposit received in February 2022; closing remained subject to conditions.

Material changes versus the prior comparable period

  • The Company issued 15.480 million Class B shares through equity distribution agreements for gross proceeds of approximately $39.765 million, increasing the year-end Class B share count to 40.451 million from 19.162 million.
  • FSD acquired Lucid in September 2021 for 4.502 million Class B shares, options and warrants with total recorded consideration of $7.291 million. The acquisition was accounted for as an asset acquisition and added $6.315 million of intellectual property.
  • FSD terminated its Phase 2 COVID-19 trial for FSD-PEA in August 2021 after a commercial-viability review concluded that the COVID-19 indication was unlikely to be commercially viable.
  • Continuing operations shifted toward FSD-PEA, Lucid-MS and Lucid-PSYCH. FSD-PEA was expected to enter Phase 2a trials in the second quarter of 2022; IND submissions for Lucid-MS and Lucid-PSYCH were anticipated by the end of 2022.
  • General and administrative expense rose materially, primarily reflecting higher professional fees, investor-relations costs, consulting costs and other administrative spending.
  • Corporate governance and management changed substantially following the May 2021 shareholder meeting. Anthony Durkacz became interim CEO, Zeeshan Saeed became President, and the former CEO, Raza Bokhari, was terminated for cause in July 2021 after an investigation by a special committee.
  • The Company incurred a C$5.5 million settlement related to a former facility-buildout class action; C$4.571 million was funded by insurance and C$0.929 million by the Company.

Outlook, commentary, risks and unusual items

  • Management expects continuing losses and negative operating cash flow for the foreseeable future. Additional financing may be required to fund research, clinical trials, regulatory activities and commercialization.
  • All three product candidates remain pre-commercial. Regulatory approval is uncertain, clinical development may be delayed or unsuccessful, and the Company relies on third-party CROs, manufacturers and single-source suppliers.
  • Lucid-PSYCH is subject to controlled-substance restrictions in the United States and Canada. Changes in psychedelic-drug regulation, licensing or public acceptance could materially affect development plans.
  • The Company relies on licensed intellectual property from Epitech and the University Health Network. License maintenance fees, milestone payments, royalties and potential termination rights may affect future economics.
  • Material contingencies include a former CEO arbitration claim seeking approximately $30.2 million in damages plus $0.5 million in aggravated and punitive damages, a Pennsylvania claim by Parkway Clinical Laboratories seeking approximately $1.413 million, a derivative complaint, an indemnity application, and a disputed CRO claim. The filing states that outcomes could not be reliably determined and, in certain cases, no provision was recorded.
  • Subsequent to year-end, FSD repurchased and cancelled 1.525 million Class B shares, issued 70,179 shares for services, cancelled 504,888 shares previously held by the former CEO, and entered into the C$16.5 million Cobourg sale agreement.
  • The Company believes it was a passive foreign investment company for U.S. federal income-tax purposes in 2021 and expected to remain one for the current year, creating potentially adverse tax consequences for U.S. investors.
  • The dual-class structure gives each Class A share 276,660 votes versus one vote per Class B share. The holders of Class A shares therefore retain significant influence despite holding only 72 shares.

Most important facts an investor should verify

  • Confirm the issuer identity: the filing is for FSD Pharma Inc. and does not reference Quantum Biopharma Ltd.
  • Review the complete audited financial statements and MD&A, particularly cash-burn assumptions, working-capital requirements and financing needs.
  • Verify the status and closing conditions of the C$16.5 million Cobourg facility and property sale.
  • Assess the clinical and regulatory milestones for FSD-PEA, Lucid-MS and Lucid-PSYCH, including expected IND and Phase 2a timing.
  • Evaluate dilution from 6.957 million outstanding warrants, 3.225 million options and potential future equity financing.
  • Review the former CEO arbitration, related-party transactions, share-cancellation proceedings and other pending litigation for possible cash exposure.
  • Confirm the Company’s PFIC status and related U.S. investor tax implications with a qualified tax adviser.